Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Marginal-zone-B-cell-lymphoma
- Focus Therapeutic Use
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 11 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 08 Mar 2015 Planned End Date changed from 1 Feb 2015 to 1 Jun 2015, according to ClinicalTrials.gov record.